RUNX3 and neoplasm: RUNX3 is an important mediator during lymphocyte differentiation into CD4+ and CD8+ cytotoxic T -lymphocytes (CTL) and natural killer cell progenitors into natural killer (NK) cells, and is thus likely pivotal in the development of anti-tumor immunity [24].